Caprock Group LLC Has $3.90 Million Holdings in Boston Scientific Co. (NYSE:BSX)

Caprock Group LLC grew its position in Boston Scientific Co. (NYSE:BSX) by 8.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 46,512 shares of the medical equipment provider’s stock after acquiring an additional 3,686 shares during the period. Caprock Group LLC’s holdings in Boston Scientific were worth $3,898,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Napa Wealth Management bought a new position in shares of Boston Scientific in the third quarter valued at about $2,295,000. Strengthening Families & Communities LLC lifted its position in shares of Boston Scientific by 9.6% during the third quarter. Strengthening Families & Communities LLC now owns 21,538 shares of the medical equipment provider’s stock worth $1,805,000 after purchasing an additional 1,887 shares in the last quarter. GLOBALT Investments LLC GA bought a new stake in shares of Boston Scientific during the third quarter valued at approximately $718,000. Quest Partners LLC increased its holdings in shares of Boston Scientific by 10.3% in the third quarter. Quest Partners LLC now owns 17,786 shares of the medical equipment provider’s stock valued at $1,490,000 after purchasing an additional 1,668 shares in the last quarter. Finally, Swiss National Bank raised its position in Boston Scientific by 0.3% in the 3rd quarter. Swiss National Bank now owns 4,363,600 shares of the medical equipment provider’s stock worth $365,670,000 after purchasing an additional 11,600 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 132,527 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $85.00, for a total transaction of $11,264,795.00. Following the sale, the executive vice president now owns 160,467 shares in the company, valued at $13,639,695. This represents a 45.23 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $83.86, for a total transaction of $585,594.38. Following the completion of the transaction, the executive vice president now directly owns 34,748 shares of the company’s stock, valued at $2,913,967.28. This represents a 16.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 309,270 shares of company stock worth $26,196,718 in the last three months. Insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the company. Canaccord Genuity Group increased their price objective on Boston Scientific from $88.00 to $98.00 and gave the company a “buy” rating in a research report on Monday, October 21st. JPMorgan Chase & Co. lifted their price objective on Boston Scientific from $82.00 to $85.00 and gave the stock an “overweight” rating in a research report on Thursday, July 25th. Barclays upped their target price on shares of Boston Scientific from $78.00 to $86.00 and gave the company an “overweight” rating in a research report on Thursday, August 22nd. Citigroup boosted their price target on shares of Boston Scientific from $92.00 to $98.00 and gave the stock a “buy” rating in a research note on Thursday, October 24th. Finally, Sanford C. Bernstein raised their price objective on shares of Boston Scientific from $92.00 to $100.00 and gave the company an “outperform” rating in a research note on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $93.39.

Boston Scientific Stock Down 0.2 %

NYSE:BSX opened at $90.30 on Wednesday. The company has a market cap of $133.09 billion, a PE ratio of 74.63, a PEG ratio of 2.56 and a beta of 0.79. The stock has a 50-day simple moving average of $85.56 and a 200 day simple moving average of $79.84. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. Boston Scientific Co. has a 52-week low of $53.93 and a 52-week high of $91.08.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.04. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The company had revenue of $4.21 billion for the quarter, compared to the consensus estimate of $4.04 billion. During the same period last year, the company earned $0.50 earnings per share. The firm’s revenue was up 19.3% compared to the same quarter last year. On average, sell-side analysts expect that Boston Scientific Co. will post 2.46 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.